ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody

    TORONTO, Jan. 31 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that it has entered into a cGMP contract manufacturing
agreement for its Trop-2 Signal Transduction Antibody Program with Laureate
Pharma, a full-service biopharmaceutical development and protein production
company located in Princeton, New Jersey. ARIUS' Trop-2 antibody program
targets a novel marker that has been linked in the scientific literature to
aggressive cancers including pancreatic, colon, breast and prostate cancer.
    "The initiation of manufacturing for our second drug candidate
demonstrates our ability to execute on our milestones and move multiple
candidates from the ARIUS pipeline of drug candidates forward," said Dr. David
S. Young, President and Chief Executive Officer of ARIUS. "Laureate Pharma has
a track record of expertise in biopharmaceutical manufacturing, including
capabilities in both clinical and commercial-grade materials and will provide
us with a supply of our Trop-2 targeting drug necessary to begin our
preclinical studies in the first quarter of 2008 in preparation for human
clinical trials."
    "Our specialized experience in the manufacture of monoclonal antibodies
makes us an ideal partner to support ARIUS and the manufacturing of their
Trop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President
& CEO of Laureate. "As with all of our Life Science client companies, we will
work closely with the ARIUS team to help them achieve their manufacturing
    ARIUS' Trop-2 Signal Transduction Antibody Program has produced the only
unconjugated antibody currently in development targeting this novel marker.
Trop-2 is a protein expressed on the cell-surface and found in many cancer
indications including pancreatic, colon, breast and prostate cancer. The
target is thought to be a key part of the expansive MAPK pathway. Of more than
900 abstracts considered for oral presentation at the October 2007
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics, the abstract on Trop-2 was one of 12 selected. The Trop-2 Signal
Transduction Program was generated using ARIUS' proprietary FunctionFIRST(TM)
technology, which selects antibodies based on their ability to kill cancer

    About Laureate Pharma, Inc.

    Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate Pharma
offers superior bioprocessing services that accelerate new products from
development through production. Laureate provides a wide range of specialized
services from process design and development to full-scale cGMP production,
purification, aseptic filling, testing, validation, analytical services, and
regulatory support. Laureate is focused on two active segments of the
biopharmaceutical industry: monoclonal antibodies and recombinant protein
products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics,
Inc. (NYSE:   SFE), which provides growth capital for entrepreneurial and
innovative technology and life sciences companies through expansion
financings, corporate spin-outs, management buyouts, recapitalizations,
industry consolidations and early-stage financings. ( For
more information, contact Michael Cavanaugh, Vice President Sales, Marketing,
and Business Development at (609) 919-3400, or or

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than
500 antibody candidates. In addition to the antibodies it is developing
in-house, ARIUS has ongoing partnerships with key biotechnology and drug
development companies. ARIUS is listed on the TSX under the symbol "ARI". For
further information, visit

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00013708E

For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,,; James Smith, Investor
Relations, (416) 815-0700 ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890